|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Adjuvant Therapy for Elderly Patients with HER2-Positive Disease
Track 7
 DR LOVE: Dennis, do you feel that trastuzumab, either alone or
with endocrine therapy, is a reasonable clinical approach for elderly
patients with ER-positive, HER2-positive tumors that are small and
node-negative? |
DR SLAMON: I have used that regimen for patients when I’ve been concerned
about the toxicity associated with chemotherapy, being aware of the fact that
good data are showing that chronologic age isn’t the factor — it has to be
performance status.
I believe the study that Chuck Vogel led showed convincingly that trastuzumab monotherapy can be effective in a patient population with metastatic disease, and not even restricted to the older patient population.
DR LOVE: Let me ask you about an 86-year-old patient we discussed in
one of our Meet The Professors sessions. The patient had HER2-positive,
ER-positive disease with five positive nodes, had some Parkinson’s disease
and was frail.
The oncologist was concerned about a taxane. Would you consider administering chemotherapy to this patient?
DR SWAIN: If she were especially frail, I would administer an aromatase
inhibitor and trastuzumab. If she were in good health, I wouldn’t administer
an anthracycline, not at age 86, because I’m sure she has the usual comorbidities
of that age group. I would use something that’s not as data driven, such as
weekly paclitaxel.
 |
 |
TOPICS
Adjuvant Chemotherapy for Patients with HER2-Negative Disease
Adjuvant Systemic Therapy for Patients with HER2-Positive Disease
Adjuvant Therapy for Elderly Patients with HER2-Positive Disease
Adjuvant Trial Evaluating Trastuzumab and/or Lapatinib in HER2-Positive Disease
- Select publications
Role of Bevacizumab for Patients with HER2-Negative Metastatic Disease
Adjuvant Trial Combining Bevacizumab with Trastuzumab
Optimizing First-Line Systemic Therapy for Patients with ER-Positive, HER2-Positive Metastatic Disease
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
